Why the study?
No treatment is proved to be efficient in metastatic epithelioid hemangioendothelioma, and median survival of patients with metastatic pleural disease is poor.
Does oral vinorelbine maintenance therapy improve progression-free survival in metastatic epithelioid hemangioendothelioma?
Does oral vinorelbine maintenance therapy improve progression-free survival in metastatic epithelioid hemangioendothelioma?
Oral vinorelbine maintenance therapy may provide prolonged progression-free survival in patients with metastatic epithelioid hemangioendothelioma.
Should not yet change practice; leaves open metronomic vinorelbine for prospective testing in metastatic EHE.
Epithelioid hemangioendothelioma (EHE) is a very rare vascular tumor, originating from endothelial cells. The etiology of EHE is unknown, yet at the molecular level, different angiogenic stimulators may act as promoters of endothelial cell proliferation. The tumor affects more commonly the lung, the liver and the bones but it can affect any other organ. Due to its heterogeneous presentation and its rarity it is often misdiagnosed. No treatment is proved to be efficient in metastatic EHE and the median survival of patients with metastatic pleural disease is generally poor, less than one year. we report a case of a 57-year-old female with multiple metastatic EHE including pleural, diagnosed by medical thoracoscopy, with a progression-free survival of 24 months with oral vinorelbine as maintenance therapy after combination of cisplatin-vinorelbine. We believe that this therapy might be of value to test in this patient population as it has never been tested before.
No takes yet. Share an insight, caveat, or question.
Anevlavis et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: